-
-
Call more information
660-596-2224 -
ASA Monitor November 2023, Vol. 87, 36. Anesthesiologists continue to be featured in naloxone coverage In June, a WebMD.com article featured an interview with Bonnie Milas, MD, a member of ASA’s Committee on Trauma and Emergency Preparedness, discussing the importance of expanded access to over-the-counter naloxone, after it received approval by the U.S. Food and […]
Read MoreAuthors: Antonio Hernandez Conte, MD, MBA, FASA et al ASA Monitor November 2023, Vol. 87, 16–17. Despite the perceived lack of visibility of LGBTQ+ anesthesiologists, many of us work proudly alongside most of you in community practices, academic medical centers, and ambulatory surgery centers. Many of you may know who “we” are, and collectively the anesthesiologist […]
Read MoreASA Monitor November 2023, Vol. 87, 36. ASA guidance on popular diabetes and weight-loss medications receives coverage in top outlets Starting in June, ASA received historic media coverage when it released guidance to withhold glucagon-like peptide-1 (GLP-1) receptor agonists used for diabetes and weight loss (such as Ozempic® and Wegovy®) before elective surgery to reduce the […]
Read MoreASA Monitor November 2023, Vol. 87, 32. Variable response to sugammadex (June 2023) The sugammadex doses recommended for reversal of neuromuscular block are based on the train-of-four response to nerve stimulation. However, the efficacy varies with such fixed doses. In a prospective study of 97 surgical patients who received rocuronium for paralysis, 13% had residual neuromuscular […]
Read MoreAuthor: Madeline Talbot ASA Monitor November 2023, Vol. 87, 30. There’s a reason why medical dramas have dominated the television sphere for decades: the hospital presents the perfect setting for considerable clashes between individuals, with high consequences. Determining whether an individual’s behavior is disruptive or just unfavorable can be challenging, but there are resources and guidelines […]
Read More